Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.
Also called NCT05769868
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Phase 3
- Enrolled
- 1,000 participants
- Registry
-
NCT05769868 -
2021-003889-12
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Spain
- Registry status
- Recruiting
Technical summary
Registry record NCT05769868. Allocation not applicable; no masking; primary purpose diagnostic. Start 2023-04-18 (actual); primary completion 2027-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
- Acronym
- CIBERbBECHO
- Condition
- Cirrhosis
- Condition
- Diabetes Mellitus
- Condition
- Oncologic Disorders
- Intervention (Drug)
- Esmolol Injection [Brevibloc]
- Lead sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
- Collaborator
- Instituto de Salud Carlos III
Record details
- Record id
cardio:ct-nct05769868- Content hash
eecba5505989d69c988cdda01e6129553e08f27ba4e46384dcd2b0638e469c9f